In Vitro Discriminative Antipseudomonal Properties Resulting from Acyl Substitution of N-Terminal Sequence of Dermaseptin S4 Derivatives

Chemistry and Biology

Volumn 14, Issue 1, 2007, Pages 75-85

  Marynka, Keren ^a   Rotem, Shahar ^a   Portnaya, Irina ^a   Cogan, Uri ^a   Mor, Amram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

CHEMBIOL; MICROBIOL

Indexed keywords

AMPHIBIAN PROTEIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; DERMASEPTIN; LIPOPOLYSACCHARIDE;

ACYLATION; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL MEMBRANE; CHEMISTRY; DRUG EFFECT; HEMOLYSIS; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; PSEUDOMONAS; STRUCTURE ACTIVITY RELATION; ULTRASTRUCTURE;

ACYLATION; AMINO ACID SEQUENCE; AMPHIBIAN PROTEINS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE; HEMOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 33846397753     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2006.11.009     Document Type: Article

References (75)

1. Brown K.L., and Hancock R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18 (2006) 24-30
2. Lehrer R.I. Primate defensins. Nat. Rev. Microbiol. 2 (2004) 727-738
3. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3 (2003) 710-720
4. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
5. Wu Z., Cocchi F., Gentles D., Ericksen B., Lubkowski J., Devico A., Lehrer R.I., and Lu W. Human neutrophil α-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett. 579 (2005) 162-166
6. VanCompernolle S.E., Taylor R.J., Oswald-Richter K., Jiang J., Youree B.E., Bowie J.H., Tyler M.J., Conlon J.M., Wade D., Aiken C., et al. Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J. Virol. 79 (2005) 11598-11606
7. Lorin C., Saidi H., Belaid A., Zairi A., Baleux F., Hocini H., Belec L., Hani K., and Tangy F. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 334 (2005) 264-275
8. Chang T.L., Vargas Jr. J., DelPortillo A., and Klotman M.E. Dual role of α-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest. 115 (2005) 765-773
9. Owen S.M., Rudolph D., Wang W., Cole A.M., Sherman M.A., Waring A.J., Lehrer R.I., and Lal R.B. A θ-defensin composed exclusively of D-amino acids is active against HIV-1. J. Pept. Res. 63 (2004) 469-476
10. Viejo-Diaz M., Andres M.T., and Fierro J.F. Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob. Agents Chemother. 49 (2005) 2583-2588
11. Avrahami D., and Shai Y. A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J. Biol. Chem. 279 (2004) 12277-12285
12. Giacometti A., Cirioni O., Barchiesi F., Caselli F., and Scalise G. In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. J. Antimicrob. Chemother. 44 (1999) 403-406
13. Dagan A., Efron L., Gaidukov L., Mor A., and Ginsburg H. In vitro antiplasmodium effects of dermaseptin S4 derivatives. Antimicrob. Agents Chemother. 46 (2002) 1059-1066
14. Efron L., Dagan A., Gaidukov L., Ginsburg H., and Mor A. Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture. J. Biol. Chem. 277 (2002) 24067-24072
15. Krugliak M., Feder R., Zolotarev V.Y., Gaidukov L., Dagan A., Ginsburg H., and Mor A. Antimalarial activities of dermaseptin S4 derivatives. Antimicrob. Agents Chemother. 44 (2000) 2442-2451
16. Chalk R., Townson H., and Ham P.J. Brugia pahangi: the effects of cecropins on microfilariae in vitro and in Aedes aegypti. Exp. Parasitol. 80 (1995) 401-406
17. Chen J., Xu X.M., Underhill C.B., Yang S., Wang L., Chen Y., Hong S., Creswell K., and Zhang L. Tachyplesin activates the classic complement pathway to kill tumor cells. Cancer Res. 65 (2005) 4614-4622
18. Risso A., Braidot E., Sordano M.C., Vianello A., Macri F., Skerlavaj B., Zanetti M., Gennaro R., and Bernardi P. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol. Cell. Biol. 22 (2002) 1926-1935
19. Mai J.C., Mi Z., Kim S.H., Ng B., and Robbins P.D. A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 61 (2001) 7709-7712
20. Boman H.G. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 254 (2003) 197-215
21. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 3 (2005) 238-250
22. Friedrich C.L., Moyles D., Beveridge T.J., and Hancock R.E. Antibacterial action of structurally diverse cationic peptides on Gram-positive bacteria. Antimicrob. Agents Chemother. 44 (2000) 2086-2092
23. Friedrich C.L., Rozek A., Patrzykat A., and Hancock R.E.W. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against Gram-positive bacteria. J. Biol. Chem. 276 (2001) 24015-24022
24. Otvos Jr. L., O I., Rogers M.E., Consolvo P.J., Condie B.A., Lovas S., Bulet P., and Blaszczyk-Thurin M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 39 (2000) 14150-14159
25. Hancock R.E., and Rozek A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol. Lett. 206 (2002) 143-149
26. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1462 (1999) 1-10
27. Wu M., Maier E., Benz R., and Hancock R.E. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38 (1999) 7235-7242
28. Huang H.W. Action of antimicrobial peptides: two-state model. Biochemistry 39 (2000) 8347-8352
29. Hancock R.E., and Chapple D.S. Peptide antibiotics. Antimicrob. Agents Chemother. 43 (1999) 1317-1323
30. Matsuzaki K. Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim. Biophys. Acta 1376 (1998) 391-400
31. Ge Y., MacDonald D.L., Holroyd K.J., Thornsberry C., Wexler H., and Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43 (1999) 782-788
32. Navon-Venezia S., Feder R., Gaidukov L., Carmeli Y., and Mor A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 46 (2002) 689-694
33. Andres E., and Dimarcq J.L. Clinical development of antimicrobial peptides. Int. J. Antimicrob. Agents 25 (2005) 448-449
34. Giles F.J., Rodriguez R., Weisdorf D., Wingard J.R., Martin P.J., Fleming T.R., Goldberg S.L., Anaissie E.J., Bolwell B.J., Chao N.J., et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk. Res. 28 (2004) 559-565
35. Trotti A., Garden A., Warde P., Symonds P., Langer C., Redman R., Pajak T.F., Fleming T.R., Henke M., Bourhis J., et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 674-681
36. Radzishevsky I.S., Rotem S., Zaknoon F., Gaidukov L., Dagan A., and Mor A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob. Agents Chemother. 49 (2005) 2412-2420
37. Yaron S., Rydlo T., Shachar D., and Mor A. Activity of dermaseptin K4-S4 against foodborne pathogens. Peptides 24 (2003) 1815-1821
38. Gaidukov L., Fish A., and Mor A. Analysis of membrane-binding properties of dermaseptin analogues: relationships between binding and cytotoxicity. Biochemistry 42 (2003) 12866-12874
39. Kustanovich I., Shalev D.E., Mikhlin M., Gaidukov L., and Mor A. Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J. Biol. Chem. 277 (2002) 16941-16951
40. Feder R., Nehushtai R., and Mor A. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides 22 (2001) 1683-1690
41. Feder R., Dagan A., and Mor A. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J. Biol. Chem. 275 (2000) 4230-4238
42. 2-terminal α-helical domain 1-18 of dermaseptin is responsible for antimicrobial activity. J. Biol. Chem. 269 (1994) 1934-1939
43. Pouny Y., Rapaport D., Mor A., Nicolas P., and Shai Y. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 31 (1992) 12416-12423
44. Rotem S., Radzishevsky I., and Mor A. Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives. Antimicrob. Agents Chemother. 50 (2006) 2666-2672
45. Avrahami D., and Shai Y. Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry 41 (2002) 2254-2263
46. Park C.B., Yi K.S., Matsuzaki K., Kim M.S., and Kim S.C. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. USA 97 (2000) 8245-8250
47. Zasloff M., Martin B., and Chen H.C. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc. Natl. Acad. Sci. USA 85 (1988) 910-913
48. Govan J.R. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J. Cyst. Fibros. 1 (2002) 203-208
49. Werthen M., Davoudi M., Sonesson A., Nitsche D.P., Morgelin M., Blom K., and Schmidtchen A. Pseudomonas aeruginosa-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer. J. Antimicrob. Chemother. 54 (2004) 772-779
50. Tossi A., Scocchi M., Zanetti M., Gennaro R., Storici P., and Romeo D. An approach combining rapid cDNA amplification and chemical synthesis for the identification of novel, cathelicidin-derived, antimicrobial peptides. Methods Mol. Biol. 78 (1997) 133-150
51. Blondelle S.E., Takahashi E., Houghten R.A., and Perez-Paya E. Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries. Biochem. J. 313 (1996) 141-147
52. Malina A., and Shai Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem. J. 390 (2005) 695-702
53. Blondelle S.E., and Houghten R.A. Novel antimicrobial compounds identified using synthetic combinatorial library technology. Trends Biotechnol. 14 (1996) 60-65
54. Rezansoff A.J., Hunter H.N., Jing W., Park I.Y., Kim S.C., and Vogel H.J. Interactions of the antimicrobial peptide Ac-FRWWHR-NH2 with model membrane systems and bacterial cells. J. Pept. Res. 65 (2005) 491-501
55. Andreu D., Ubach J., Boman A., Wahlin B., Wade D., Merrifield R.B., and Boman H.G. Shortened cecropin A-melittin hybrids. Significant size reduction retains potent antibiotic activity. FEBS Lett. 296 (1992) 190-194
56. Beven L., Castano S., Dufourcq J., Wieslander A., and Wroblewski H. The antibiotic activity of cationic linear amphipathic peptides: lessons from the action of leucine/lysine copolymers on bacteria of the class Mollicutes. Eur. J. Biochem. 270 (2003) 2207-2217
57. Juvvadi P., Vunnam S., Merrifield E.L., Boman H.G., and Merrifield R.B. Hydrophobic effects on antibacterial and channel-forming properties of cecropin A-melittin hybrids. J. Pept. Sci. 2 (1996) 223-232
58. Subbalakshmi C., Nagaraj R., and Sitaram N. Biological activities of C-terminal 15-residue synthetic fragment of melittin: design of an analog with improved antibacterial activity. FEBS Lett. 448 (1999) 62-66
59. Yan H., Li S., Sun X., Mi H., and He B. Individual substitution analogs of Mel(12-26), melittin's C-terminal 15-residue peptide: their antimicrobial and hemolytic actions. FEBS Lett. 554 (2003) 100-104
60. Brogden K.A., Ackermann M., McCray Jr. P.B., and Tack B.F. Antimicrobial peptides in animals and their role in host defences. Int. J. Antimicrob. Agents 22 (2003) 465-478
61. Powers J.P., and Hancock R.E.W. The relationship between peptide structure and antibacterial activity. Peptides 24 (2003) 1681-1691
62. Tossi A., Sandri L., and Giangaspero A. Amphipathic, α-helical antimicrobial peptides. Biopolymers 55 (2000) 4-30
63. Shalev D.E., Mor A., and Kustanovich I. Structural consequences of carboxyamidation of dermaseptin S3. Biochemistry 41 (2002) 7312-7317
64. Shalev D.E., Rotem S., Fish A., and Mor A. Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K4-S4-(1-13). J. Biol. Chem. 281 (2006) 9432-9438
65. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1 (2001) 156-164
66. Ding L., Yang L., Weiss T.M., Waring A.J., Lehrer R.I., and Huang H.W. Interaction of antimicrobial peptides with lipopolysaccharides. Biochemistry 42 (2003) 12251-12259
67. Papo N., and Shai Y. A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J. Biol. Chem. 280 (2005) 10378-10387
68. Lockwood N.A., Haseman J.R., Tirrell M.V., and Mayo K.H. Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains. Biochem. J. 378 (2004) 93-103
69. Ghosh J.K., Shaool D., Guillaud P., Ciceron L., Mazier D., Kustanovich I., Shai Y., and Mor A. Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparum and the underlying molecular basis. J. Biol. Chem. 272 (1997) 31609-31616
70. Fields G.B., and Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35 (1990) 161-214
71. Harwig S.S., Waring A., Yang H.J., Cho Y., Tan L., and Lehrer R.I. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Eur. J. Biochem. 240 (1996) 352-357
72. Gustavsson B., and Betner I. Fully automated amino acid analysis for protein and peptide hydrolysates by precolumn derivatization with 9-fluorenyl methylchloroformate and 1-aminoadamantane. J. Chromatogr. 507 (1990) 67-77
73. Steinberg D.A., and Lehrer R.I. Designer assays for antimicrobial peptides. Disputing the "one-size-fits-all" theory. Methods Mol. Biol. 78 (1997) 169-186
74. Zhang L., Dhillon P., Yan H., Farmer S., and Hancock R.E. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44 (2000) 3317-3321
75. Allende D., and McIntosh T.J. Lipopolysaccharides in bacterial membranes act like cholesterol in eukaryotic plasma membranes in providing protection against melittin-induced bilayer lysis. Biochemistry 42 (2003) 1101-1108